Shares mag. recommending this stock this week. Is this going to be our killer this christmas!!!! any comments anyone?????

stock hangover! brokers obviously have plenty to get rid of and people who bought cheaper cycling out - give it time for the washout and then watch it motor to 12 within 3 months - prob rest there

stock hangover! brokers obviously have plenty to get rid of and people who bought cheaper cycling out - give it time for the washout and then watch it motor to 12 within 3 months - prob rest there

The Guardian said yesterday

Talk that CeNes Pharmaceuticals (LSE: CEN.L - news) could be given the green light by US regulators to start Phase III clinical trials of its treatment for severe post-operative pain.

Shares recommended Aug 2004 and still the same? Oh dear. Phase 3 my arse. And even then it won't necessarily deliver. Just another aim loser.

although i agree with your analysis, will probably trade 4p-12p over the next 6 months. as ever buy on the cannons sell on the bugles. a merry christmas and a profitable new year to all cen players

All research points to cenes rising in '06. I had the same opinion of seo (+200 per cent in '05) this time last year! IMHO & DYOR of course.

Best wishes to all for the new year.

jtf


Info:- http://www.fillyaboots.com/f7/forum_posts.asp?TID=1880&KW=cenes

NEWS:Talk that an institution is about to announce it has taken a 3% stake, lifts CeNes Pharmaceuticals. Hopefully pushes share price upwards

A nice little snippet of news:

CeNeS Pharmaceuticals said it has been granted a patent on its short-acting sedatives by the European Patent Office (EPO).

The patent covers a series of sedative compounds, including CNS 7056X, which are in pre-clinical development.

The EPO is the first to grant the patent.

The company said national applications are pending in other key territories including the US and Japan.

CeNeS' short-acting sedatives are being developed for use in patients undergoing short diagnostic and surgical procedures.

Check this out Cenes Looks like it is going places this year. Buy now, looks very undervalued

Dr.Neil Clark wallstreet interview 17/3/06
http://www.wallstreetreporter.com/linked.php?id=16769

Cenes Moving gradually up, lot of results out soon. Better get in this share quick befor you miss out. Big institutions in.

Let's hope so - it's been a long time coming!

Cenes 26th May 2006 Research Report available at the site below :

http://www.objectivecapital.co.uk/

http://www.proactiveinvestors.com/

Just found this article.Very promising indeed.
The site is free to register on and to read the article.Useful site for those that have not seen it.

CeNes: Future looks bright.
By William Foss.

Restructuring a publicly listed company is a painstaking and tedious operation. Over the past three years, CeNes, a pharmaceutical junior, has been the subject of an intense restructuring program to get the company refocused on drug discovery. Cenes went under the knife in an attempt to streamline it's pipeline and build up a cash reserve.

Thanks h.hairettin.

Good news from CeNeS, particularly the bit about potential revenue stream. I notice someone jumped in yesterday with a late reported trade this morning. Must be nice to have inside information.

pth

CeNeS Pharmaceuticals PLC
13 June 2006


Data on CeNeS short-acting sedative to be presented at at the American Society
for Anesthesiology meeting, 2006.


Cambridge, UK, 13th June 2006 - CeNeS Pharmaceuticals plc (AIM: CEN) ('CeNeS' or
'the Company') today announced that four abstracts highlighting the profile of
the short-acting sedative, CNS 7056X, have been accepted for presentation at the
American Society for Anesthesiology (ASA) meeting to be held in Chicago on
14-18th October 2006. One of the abstracts has been selected as a high profile
platform presentation.

The data to be presented at the ASA meeting will highlight the very encouraging
pre-clinical profile of CNS 7056X, including new results showing a rapid onset
and offset of sedative action and rapid metabolism by human liver samples. The
compound is being developed primarily as a sedative for short non-surgical and
surgical procedures. In addition, on the basis of these new data, CeNeS is now
evaluating the potential of CNS 7056X for use in the induction and maintenance
of anaesthesia. Pre-clinical studies to evaluate the potential of CNS 7056X in
these additional indications are being undertaken at The University of
Strasbourg, The University of Adelaide and under a Material Transfer Agreement
at a major pharmaceutical company. The evaluation will complete in the second
half of 2006. Extending the development of CNS 7056X to include the induction
and maintenance of anaesthesia could double the estimated potential market
opportunity to over 400m.

CNS 7056X is the lead compound of a series that was assigned to CeNeS from
GlaxoSmithKline in November 2003. Pre-clinical development work is ongoing with
the intention of filing an IND in the U.S. in 2006. Thereafter, CeNeS is
planning to conduct the first proof of concept Phase I study in the U.S., a
major potential market for short acting sedatives.


Neil Clark, Chief Executive, commented: 'The American Society for Anesthesiology
meeting is the largest gathering of anaesthesiologists in the world with up to
18,000 attendees expected. We are delighted to see that data on our short-acting
sedative will be presented at such an important conference. We are also very
excited by the potential of CNS 7056X for the additional indications of
induction and maintenance of anaesthesia. Presenting at this conference will
enable to us to access key opinion leaders and potential global partners of CNS
7056X'

CeNeS. Phase III study of M6G is to go head to head with morphine.. The study will be made double blind in a way that carer nor patient will be aware of which treatment is being given.. Six Euro countries will be involved, giving a total of twenty sites

CeNeS is out to prove that their M6G drug works faster, giving a lower levels of nausea and a fair comparison of pain management. The study will allow patients to self administer a dose of M6G..

In a nutshell CeNeS is after the sales of M6G for post operative pain.. The market could reach 200m PA.. The next stage as I see it is to secure the valuable licensing agreement.. with partners who are able to offer strong marketing off this major drug to be

The interim results are out visit CeNeS website Over the next few months there should be a steady flow of news Any one out there in on this one

I am myway. Have been holding for some time now and frustrated by the lack of newsflow. If that's about to change so much the better. Seems they're pretty confident of M6G......

Hi queen... as far as I see it M6G is the key to the next stage of CEN SP movment.. I feel that so many companies let them selves down through lack of news flow...

Indeed....as long as it's good news flow!!

The proof of the pudding take time out and read the CeNeS PH Plc write-up in last weeks Investors Chronicle M6G the new pain relief drug to-be.. Is now working through its phase III trials.. Look out for data on the trials by the year end or early 2007.

The company is running short of cash, however the late stage trials for M6G and phase II trials for diabetic neuropathic pain drug CNS5161 should come good.. For cash flow as potential partners are keeping their eyes on the trials

Just what are we looking here a possible replacement for morphine.. I will say no more..